关于杭州安旭生物科技股份有限公司 2023 年报问询函的回复 众环专字(2024)0300150 号 上海证券交易所科创板公司管理部： 中审众环会计师事务所（特殊普通合伙）（以下简称"本所"或"我们"）作为杭州安旭 生物科技股份有限公司（以下简称"安旭生物"或"公司"）2023 年度财务报表的审计机构， 于 2024 年 4 月 28 日出具了众环审字（2024）0300556 号无保留意见审计报告。 根据贵所《关于杭州安旭生物科技股份有限公司 2023 年年度报告的信息披露监管问询 函》（"上证科创公函【2024】0093 号，以下简称《问询函》"）的要求，我们以对安旭生物 相关财务报表执行的审计工作为依据，对问询函中需要本所回复的相关问题进行了核查，现 将核查情况说明如下： 问题一、关于流动资产管理 截至 2023 年 12 月 31 日，公司货币资金余额 33,735.54 万元，占资产总额 5.83%，因 进行现金管理购买的存单、理财产品账面余额为人民币 394,061.01 万元，占资产总额的 68.06%。公司使用自有资金 1 亿元购买了隆晟 1 号信托产品，上述产品已逾期尚未兑付， 公司确认了 ...

证券代码：688075 证券简称：安旭生物 公告编号：2024-020 杭州安旭生物科技股份有限公司 关于对上海证券交易所 2023 年年度报告问询函回复的公告 杭州安旭生物科技股份有限公司（以下简称"公司"）于近日收到上海证券交 易所科创板公司管理部下发的《关于杭州安旭生物科技股份有限公司 2023 年年 度报告的信息披露监管问询函》（上证科创公函【2024】0093 号，以下简称"《问 询函》"），要求公司对相关事项做出书面说明。 收到《问询函》后，公司高度重视，立即组织公司相关人员和相关中介机 构对《问询函》提及的问题进行逐项核查落实。截至目前，公司和相关中介机构 已对《问询函》中相关问题完成了确认工作，中介机构也已经出具相关专项说明。 公司对《问询函》的答复具体如下： 问题 1：关于流动资产管理 截至2023年12月31日，公司货币资金余额33,735.54万元，占资产总额5.83%，因进行现 金管理购买的存单、理财产品账面余额为人民币394,061.01万元，占资产总额的68.06%。公 司使用自有资金1亿元购买了隆晟1号信托产品，上述产品已逾期尚未兑付，公司确认了3500 万元公允价值变动损失。请 ...

杭州安旭生物科技股份有限公司 2023 年年报问询函回复 民生证券股份有限公司 关于杭州安旭生物科技股份有限公司 2023 年年度报告的信息披露监管问询函回复的核查意见 上海证券交易所： 根据贵所《关于杭州安旭生物科技股份有限公司 2023 年年度报告的信息披露监 管问询函》（上证科创公函[2024]0093 号，以下简称《问询函》）的要求，民生证券 股份有限公司（以下简称"民生证券"或"持续督导机构"）作为杭州安旭生物科 技股份有限公司（以下简称"安旭生物"或"公司"）的持续督导机构，会同公司 及相关中介机构，对问询函所提及的事项进行了逐项落实、核查。现将审核问询函 的回复上报贵所，请审核。 1 | 问题一、关于流动资产管理 | 3 | | --- | --- | | 问题二、关于应收账款 | 7 | | 问题三、关于存货 | 11 | | 问题四、关于分季度财务数据 | 16 | | 问题五、关于预付款项 | 18 | | 问题六、关于固定资产 | 20 | | 问题七、关于境外业务 | 23 | 杭州安旭生物科技股份有限公司 2023 年年报问询函回复 问题一、关于流动资产管理 截至 2023 年 12 ...

民生证券股份有限公司 关于杭州安旭生物科技股份有限公司 2023 年度持续督导工作现场检查报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法律、 法规的规定，民生证券股份有限公司（以下简称"保荐机构"）作为杭州安旭 生物科技股份有限公司（以下简称"安旭生物"或"公司"）首次公开发行股 票并在科创板上市的保荐机构，对公司 2023 年度（以下简称"本持续督导 期"）的规范运作情况进行了现场检查，现就有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构 民生证券股份有限公司 （二）保荐代表人 孙闽、朱仙掌 （三）现场检查时间 2024 年 5 月 15 日 （四）现场检查人员 朱仙掌 （五）现场检查内容 公司治理、内部控制，信息披露，独立性以及与控股股东、实际控制人及 其他关联方资金往来情况，募集资金使用，关联交易、对外担保、重大对外投 资，经营状况等。 （六）现场检查手段 1、查看公司主要生产经营场所，对公司相关人员进行访谈； 1 2、查阅本持续督导期间公司召开的历次三会文件； 3、查阅本持续督导期间公司的信 ...

杭州安旭生物科技股份有限公司 2023 年年度股东大会会议资料 杭州安旭生物科技 股份有限公司 2023 年年度股东大会会议资料 股票简称：安旭生物 股票代码：688075 2024 年 5 月 23 日 1 杭州安旭生物科技股份有限公司 2023 年年度股东大会会议资料 目 录 | 年年度股东大会须知……………………………………………………………………………..………3 | 2023 | | --- | --- | | 年年度股东大会议程…………………………………………………………………..…………………5 | 2023 | | 年度董事会工作报告》的议案……………….…………..……………………7 | 议案一：关于《2023 | | 年度监事会工作报告》的议案……………………………………………….13 | 议案二：关于《2023 | | 年年度报告及其摘要》的议案………………………………………17 | 议案三：关于《公司 2023 | | 年度财务决算报告》的议案………………………………………18 | 议案四：关于《公司 2023 | | 年度利润分配预案的议案………………………………………………24 | ...

证券代码：688075 证券简称：安旭生物 公告编号：2024-018 杭州安旭生物科技股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次投资者说明会以网络互动形式召开，公司将针对 2023 年度及 2024 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 重要内容提示： 会议召开时间：2024 年 05 月 16 日(星期四) 下午 13:00-14:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 05 月 09 日(星期四) 至 05 月 15 日(星期三)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 jun.yu@di ...

Financial Performance - The company's revenue for 2023 was approximately ¥503.36 million, a decrease of 91.84% compared to ¥6.17 billion in 2022[24]. - Net profit attributable to shareholders was approximately ¥141.55 million, down 95.35% from ¥3.04 billion in the previous year[24]. - The net profit after deducting non-recurring gains and losses was approximately ¥52.35 million, a decline of 98.25% from ¥2.98 billion in 2022[24]. - Cash flow from operating activities showed a net outflow of approximately ¥623.08 million, a decrease of 116.65% compared to a net inflow of ¥3.74 billion in 2022[24]. - Total assets at the end of 2023 were approximately ¥5.79 billion, down 16.71% from ¥6.95 billion at the end of 2022[24]. - Net assets attributable to shareholders decreased by 5.76% to approximately ¥5.11 billion from ¥5.42 billion in 2022[24]. - The company reported a net profit of -212,061,244.04 CNY in Q4 2023, contrasting with positive profits in the earlier quarters[28]. - The company achieved operating revenue of 503.36 million yuan in 2023, a decrease of 91.84% compared to the same period last year[122]. - The net profit attributable to the parent company was 141.55 million yuan, down 95.35% year-on-year[122]. - The total assets at the end of the reporting period reached 5.79 billion yuan, a year-on-year decrease of 16.71%[122]. - The equity attributable to the parent company was 5.11 billion yuan, down 5.76% from the end of the previous year[122]. Dividend Distribution - The company plans to distribute a cash dividend of 4 CNY per 10 shares, totaling approximately 50.83 million CNY, which represents 35.91% of the net profit attributable to shareholders for 2023[6]. - The company has a remaining undistributed profit of approximately 3.81 billion CNY after the dividend distribution[6]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures for providing guarantees[8]. - The company does not have any special arrangements for corporate governance[7]. - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors[7]. - The company received a warning letter from the China Securities Regulatory Commission on December 16, 2022, highlighting issues in compliance and information disclosure, prompting improvements in governance and financial practices[186]. - The company is committed to enhancing compliance with securities laws and regulations, as indicated by the establishment of an insider information management system[186]. Research and Development - Research and development expenses accounted for 20.91% of operating revenue, an increase of 15.57 percentage points compared to the previous year[26]. - The company added 49 new patents in 2023, including 10 invention patents, bringing the total to 261 authorized patents, of which 30 are invention patents[39]. - The company has developed a self-supply plan for core raw materials, achieving over 68% self-sufficiency in biological raw materials, which supports continuous innovation and stable production[52]. - The company has established a complete R&D, procurement, production, and sales system, forming a stable profit model primarily from the sales of in vitro diagnostic products[53]. - The company is actively researching industry trends and developing new products that align with future market directions, focusing on high-tech, high-quality, and high-precision advancements[57]. - The company has a strong pipeline of new products, with multiple patents related to cancer treatment and diagnostic biomarkers filed in 2023[90]. - The company continues to invest in research and development, as reflected in its increasing number of patent applications and granted patents over the years[90]. Market Expansion and Strategy - The company is actively expanding into pet health management, family health management, and third-party medical testing laboratory sectors[36]. - The company aims to become a leader in the POCT industry, focusing on the development of in vitro diagnostic reagents and biological raw materials[36]. - The company is expanding its marketing network, establishing subsidiaries in the U.S., Singapore, and Hong Kong, and formed a marketing matrix in key domestic cities[43]. - The company is focusing on high-throughput, closed systems, and timely molecular diagnostic technologies, which are the fastest-growing segments in the in vitro diagnostic market[71]. - The company plans to enhance its R&D capabilities, expand production capacity, and improve product quality to increase market share both domestically and internationally[157]. - The company aims to upgrade existing products and expand its product line through differentiated strategies, focusing on major project registrations and market promotions[158]. - The company is considering potential mergers and acquisitions to bolster its market position and enhance competitive advantages[174]. Risks and Challenges - The company has disclosed potential risks that may adversely affect its operations in the management discussion section[4]. - The company faces risks related to market competition, particularly in the in vitro diagnostics industry, which is attracting more entrants[114]. - The company has a risk of core technology personnel turnover, which could impact its R&D capabilities[113]. - The company is exposed to macroeconomic risks, particularly due to uncertainties in overseas sales of antigen rapid test kits[122]. Employee Management - The total number of employees in the parent company is 679, and in major subsidiaries, it is 112, resulting in a total of 791 employees[196]. - The company emphasizes employee welfare by providing five social insurances and one housing fund, meal subsidies, paid annual leave, and health check-ups[198]. - The company conducts annual employee training plans based on departmental needs and talent development, focusing on job knowledge and competency[199]. - The company has a performance-based compensation policy that includes bonuses, commissions, and project rewards to motivate employees[198]. - The average salary of R&D personnel increased to 18.75 thousand RMB, compared to 16.67 thousand RMB in the previous period[104]. Financial Health and Investments - The company registered a total of 976 certifications during the reporting period, with 893 international certifications and 83 domestic certifications[92]. - The company has completed the development of several POCT testing systems, with ongoing projects in various stages of research and development[99]. - The company has invested in a diverse range of R&D projects, including a dry biochemical platform and a food safety testing platform, with total investments of ¥63,118,000.00 and ¥34,350,000.00 respectively[97][99]. - The company plans to expand its market presence through strategic investments in the pharmaceutical and biotechnology sectors[150].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 129,406,701.97, representing a year-on-year increase of 6.53%[4] - The net profit attributable to shareholders was CNY 70,190,798.47, reflecting a significant increase of 38.09% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 19,629,646.53, which is a remarkable increase of 134.82% year-on-year[4] - Total revenue for Q1 2024 reached CNY 129.41 million, an increase of 6.9% compared to CNY 121.48 million in Q1 2023[18] - Net profit for Q1 2024 was CNY 70.33 million, up 39.7% from CNY 50.38 million in Q1 2023[19] - Earnings per share for Q1 2024 were CNY 0.55, compared to CNY 0.40 in Q1 2023, reflecting a 37.5% increase[20] Cash Flow and Assets - The net cash flow from operating activities was CNY 1,008,618.28, showing a decline of 100.84% compared to the previous year[4] - The company reported a decrease in cash flow primarily due to tax payments and employee bonuses in the previous year[8] - As of March 31, 2024, the company's cash and cash equivalents amounted to RMB 675,427,076.63, an increase from RMB 337,355,385.11 on December 31, 2023, representing a growth of 100.4%[15] - The total current assets reached RMB 4,878,653,999.22, compared to RMB 4,811,722,641.50 at the end of 2023, indicating a slight increase of 1.4%[15] - The company reported a total cash inflow from operating activities of 167,094,020.34, while cash outflow was 166,085,402.06, indicating a tight operational cash flow[22] - The company received tax refunds totaling 9,878,317.12, contributing positively to cash inflows[22] - Cash inflow from investment recoveries was 1,540,333,850.54, showing strong investment performance[22] - The company incurred cash outflows of 2,000,000.00 for debt repayment during the financing activities[23] - The net cash flow from financing activities was -2,000,000.00, indicating a reduction in cash due to debt servicing[23] - The impact of exchange rate changes on cash and cash equivalents was -436,936.44, reflecting currency fluctuations[23] - The company reported a significant increase in cash and cash equivalents by 321,664,962.88 during the quarter[23] Research and Development - The total R&D investment was CNY 19,840,217.39, which decreased by 16.54% year-on-year, accounting for 15.33% of operating revenue[4] - Research and development expenses were CNY 19.84 million, down from CNY 23.77 million, a decrease of 16.3% year-over-year[19] Shareholder Information - The company reported a total of 34,150,290 shares held by Hangzhou Aixi Holdings, accounting for 26.87% of total shares[10] - The second-largest shareholder, Ling Shisheng, holds 31,929,520 shares, representing 25.12% of total shares[10] - The company has not reported any significant changes in the top 10 shareholders due to the transfer of shares[13] - The company has a total of 1,270,832 shares held by Minsheng Securities, which is 1.00% of total shares[12] Future Outlook - The company has not disclosed any new strategies or future outlook in the current report[13] Other Financial Metrics - The basic and diluted earnings per share were both CNY 0.55, marking an increase of 38.09% compared to the same period last year[4] - The weighted average return on net assets was 0.01%, reflecting an increase of 46.71% year-on-year[4] - Total operating costs decreased to CNY 112.89 million from CNY 115.41 million, a reduction of 2.2% year-over-year[19] - Non-current assets totaled CNY 976.47 million, slightly down from CNY 977.82 million in the previous quarter[17] - Total assets increased to CNY 5.86 billion from CNY 5.79 billion, marking a growth of 1.2%[17] - Total liabilities decreased to CNY 680.23 million from CNY 683.83 million, a decline of 0.8%[17] - Deferred income tax assets rose to CNY 168.20 million from CNY 164.40 million, an increase of 2.2%[17] - Non-recurring gains and losses amounted to CNY 50,561,151.94 after tax, with significant contributions from government subsidies and other non-operating income[7]

杭州安旭生物科技股份有限公司 投资者关系活动记录表 证券简称：安旭生物 证券代码：688075 编号：2024-001 √特定对象调研 □分析师会议 □媒体采访 投资者关系 □业绩说明会 □新闻发布会 □路演活动 活动类别 □现场参观 □其他（电话会议） 广发基金、中金公司、西部证券、浙江国信、申万宏源、国金 参与单位名 证券、上海证券、开源证券、东吴资管、仁睿投资、杭州盛熙 称 基金、杭州炘卓投资、米度资本、浙江永禧、国新国同 时间 2024年3月20日14:00-16:00 地点 公司5楼大会议室 公司接待人 董事会秘书韩钧、证券事务部余钧 员姓名 ...

证券代码：688075 证券简称：安旭生物 公告编号：2024-005 杭州安旭生物科技股份有限公司 2024 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 1 月 19 日 （二） 股东大会召开的地点：浙江省杭州市莫干山路 1418-50 号 4 幢 5 楼大会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 12 | | --- | --- | | 普通股股东人数 | 12 | | 2、出席会议的股东所持有的表决权数量 | 80,621,518 | | 普通股股东所持有表决权数量 | 80,621,518 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 63.4401 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 63. ...